| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Convergent Therapeutics |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Medivation |
| Recipient: You |
| Company: Astellas Pharma |
| Recipient: You |
| Company: Dendreon |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
| Company: Genentech |
| Recipient: You |
| Company: Endocyte |
| Recipient: You |
| Company: Immunomedics |
| Recipient: You |
| Company: Karyopharm Therapeutics |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Tolmar |
| Recipient: You |
| Company: QED |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Sanofi |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Clovis Oncology |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Genomic Health |
| Recipient: You |
| Company: POINT Biopharma |
| Recipient: You |
| Company: Blue Earth Diagnostics |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
| Company: AIkido Pharma |
| Recipient: You |
| Company: 4D Pharma |
| Recipient: You |
| Company: Clarity Pharmaceuticals |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Telix Pharmaceuticals |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Myovant Sciences |
| Recipient: You |
| Company: Convergent Therapeutics |
| Recipient: You |
| Company: Hookipa Pharma |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: TransThera Biosciences |
| Recipient: You |
| Company: Bicycle Therapeutics |
| Recipient: You |
| Company: Ambrx |
| Recipient: You |
| Company: Exelixis |
| Recipient: You |
| Company: Boston Scientific |
| Recipient: You |
| Company: General Electric |
| Recipient: You |
| Company: Lantheus Medical Imaging |
| Recipient: You |
| Company: Abdera Thereapeutics |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Lilly |
| Recipient: Your Institution |
| Company: Sanofi |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Progenics |
| Recipient: Your Institution |
| Company: Millennium |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Dendreon |
| Recipient: Your Institution |
| Company: Rexahn Pharmaceuticals |
| Recipient: Your Institution |
| Company: Bayer |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
| Company: Newlink Genetics |
| Recipient: Your Institution |
| Company: Inovio Pharmaceuticals |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Immunomedics |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: AVEO |
| Recipient: Your Institution |
| Company: Boehringer Ingelheim |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Stem CentRx |
| Recipient: Your Institution |
| Company: Karyopharm Therapeutics |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Medivation |
| Recipient: Your Institution |
| Company: Endocyte |
| Recipient: Your Institution |
| Company: Exelixis |
| Recipient: Your Institution |
| Company: Clovis Oncology |
| Recipient: Your Institution |
| Company: POINT Biopharma |
| Recipient: Your Institution |
| Company: Ambrx |
| Recipient: Your Institution |
| Company: Clarity Pharmaceuticals |
| Recipient: Your Institution |
| Company: Telix Pharmaceuticals |
| Recipient: Your Institution |
| Company: Janux Therapeutics |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Patent Royalty from Immunomedics / Gilead |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Sanofi |
| Recipient: You |
| Company: Immunomedics |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Astellas Pharma |
| Recipient: You |
| Company: Telix Pharmaceuticals |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| Company: ATLAB Pharma |
| Recipient: You |
| Company: Phosplatin Therapeutics |
| Recipient: You |
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|